ArticleTranslational andrology and urology2025
Prognostic impact of nephrectomy and a prediction model for estimating the survival benefit of nephrectomy for patients with clear cell renal cell carcinoma (ccRCC).
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Valosin-Containing Protein (VCP)/p97 Expression Correlation of Prognosis of Clear Cell Renal Cell Carcinomas.Biomedicines · 2026Article
- A deep learning-based multimodal model with automated body composition analysis predicts prognosis in advanced clear cell renal cell carcinoma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The benefit of nephrectomy for all patients with clear cell renal cell carcinoma (ccRCC) remains controversial. This study assessed the impact of nephrectomy on patient prognosis and developed a prognostic model for nephrectomy-treated patients. Methods: Data were extracted from the Surveillance, Epidemiology, and End Results (SEER) and The Cancer Genome Atlas databases. Propensity score matching (PSM) was implemented, followed by univariate and multivariate survival analyses to compare overall survival (OS) between ccRCC patients treated with and without nephrectomy. Subsequently, we developed and internally validated a nomogram for predicting OS in nephrectomy-treated patients using multivariate Cox regression modeling. Results: OS was significantly better in the nephrectomy group compared to the non-nephrectomy group [hazard ratio (HR) =0.405, 95% confidence interval (CI): 0.382-0.429, P<0.001), with significant benefit observed across all predefined subgroups (all HR <1, P<0.05). Age, gender, tumor stage, tumor-node-metastasis (TNM) stage and differentiation grade were identified as independent risk factors of OS in nephrectomy-treated ccRCC patients. The nomogram incorporating these factors exhibited excellent discrimination, calibration, and clinical utility in training, internal validation, and external test cohorts. Conclusions: Nephrectomy was shown to significantly improve survival in patients with ccRCC. We developed an effective survival prediction model for these patients, which could aid in identifying high-risk individuals and providing a valuable tool for personalized survival assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.